Management

Each member of the team at Genesys Capital brings significant knowledge and expertise in the high technology and biotechnology sectors.

Kent Plumley | Co-Founder and Partner

Mr. Plumley is Co-Founder and Partner of Genesys Capital. Until his recent retirement as a partner from Osler, Hoskin & Harcourt LLP he was a member of the Business Law, Intellectual Property and Technology Law departments of that firm. During his legal and business career Mr. Plumley spent more than 35 years advising and raising venture and equity capital through private and public financing for many of Canada's successful high technology companies. These include Mitel Corporation, Newbridge Networks Corporation and several Newridge affiliate companies: Cambrian Systems Corporation, TimeStep Corporation, Vienna Systems, CrossKeys Systems Corporation and Bridgewater Systems. Mr. Plumley was also a founding investor and director of several of these companies. His high technology affiliations include Zarlink Corporation, and In-Touch Systems among others.

Mr. Plumley has been an active participant in business and community affairs throughout his career. He is a past member and ongoing supporter of the Board of Trustees and Finance and Audit Committee of The University of Ottawa Heart Institute Foundation. He is also a supporter of the newly opened Sprott Centre for Stem Cell Research, a part of the Ottawa Health Research Institute (OHRI). Other involvements include past directorships of the Stem Cell Network, Ottawa Life Sciences Council and Photonics Research Ontario (PRO). For many years he was a member of the Ottawa Centre for Research and Innovation (OCRI), Ottawa's lead economic development corporation.

In 2008 Mr. Plumley completed the maximum term of 12 years as a member of the Board of Trustees for Queen's University but remains a member of the Board's Advancement Committee and a Director of PARTEQ, the Queen's University licensing and technology transfer agency. He is a former member of the Queen's School of Business Advisory Council. He also served as a representative of Osler, Hoskin & Harcourt to the Advisory Board for the Centre for Innovation Law & Policy at the University of Toronto Law School.

Mr. Plumley earned a Bachelor of Science in Chemical Engineering from Queen's University in 1960 and an LLB in 1963, also from Queen's. He was called to the Bar of Ontario in 1965 and is a registered Patent and Trade Mark agent.

Kelly Holman | Co-Founder and Managing Director

Mr. Holman is co-Founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry. Since co-founding Genesys Capital in 2000, Mr. Holman has been actively involved in raising over $225 million of venture capital and has been instrumental in deploying over $100 million across 20 investments. He currently serves on the Board of Directors of Epocal Inc., and is a past director of Affinium Pharmaceuticals, Insception Biosciences, Interface Biologics and Zelos Therapeutics. Mr. Holman is active in deal origination and company creation and has advised Canada's National Biotechnology Advisory Committee on strategies for financing start-up and early-stage biotechnology companies.

Prior to co-founding Genesys Capital, Mr. Holman was a Senior Investment Manager with MDS Capital Corp. During his tenure at MDS, he was involved in all stages of investment from start-up and early-stage to mezzanine stage and public company investing.

Previously, Mr. Holman worked in the laboratory of Dr. Peter St George-Hyslop at the University of Toronto where he was a key member of the international research team that discovered several genes responsible for Alzheimer's disease. Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen's University.

Damian Lamb | Co-Founder and Managing Director

Mr. Lamb is co-Founder and Managing Director of Genesys Capital. He brings a unique experience base, blending skills in both the commercial and technical side of biotechnology. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $225 million in venture capital funds, and has been involved in deploying over $100 million in 20 investments. He currently serves on the Boards of Affinium Pharmaceuticals Inc., Profound Medical Inc. and the Centre for Probe Development and Commercialization at McMaster University. He has served on the Board of Ionalytics Corporation (acquired by Thermo Electron Corp.), Millenium Biologix (acquired by Medtronic) and was Chairman of the Board of DELEX Therapeutics Inc. when it was sold to YM BioSciences. Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.

Prior to co-founding Genesys Capital, Mr. Lamb was an Investment Manager with MDS Capital Corp. He is a frequently invited speaker at biotechnology industry conferences and was a judge for the BioNorth Top 10 Canadian Life Sciences Companies contest from 2000 - 2008.

Mr. Lamb graduated from McMaster University, Faculty of Health Sciences, with an M.S. in Molecular Neurobiology and also holds an MBA from Queen's University.

Jamie Stiff | Partner

Mr. Stiff joined Genesys Capital in 2002 and became partner at the firm in 2007. He brings to Genesys a unique combination of scientific understanding and business acumen and has demonstrated an innate affinity for the business of venture capital. Since joining the firm, Mr. Stiff has gained significant deal experience across a number of transactions.

Mr. Stiff currently serves on the board of Allostera Pharma and sits as an observer on the board of NeurAxon Inc. Past board roles include directorships at Matregen Corp. and Stempath Inc. and board observer at Zelos Therapeutics and Interface Biologics.

Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics arena. This experience combined with an academic background in Biology has provided significant technical knowledge of many areas of life sciences and provides for a keen eye for sourcing promising early stage deal flow through the company's proprietary Technology Access Partnerships.

Mr. Stiff holds a Bachelor of Science (Honours) in Biology from Queen's University and an MBA from the Rotman School of Management at the University of Toronto.

Jennifer Williams | Director of Finance and Operations

Ms. Williams is Director of Finance and Operations at Genesys Capital. Ms. Williams joined Genesys Capital in 2003. During her career with Genesys she has worked closely with the team to develop the operations and is responsible for finance, human resources and administration.

Ms. Williams graduated from the University of Guelph with an Honours Bachelor of Commerce and holds an MBA from Queen's University.

Frédéric Porte | Venture Partner

In 2008, Mr. Porte joined Genesys as a venture partner to provide strategic and operational support for companies within the Genesys portfolio and help to identify new investment opportunities.

Mr. Frédéric Porte is a seasoned entrepreneur and businessman with more than 25 years of experience in the life sciences industry. During his career, Mr. Porte has founded three successful companies. He is currently the President and Founder of Medipress Management Inc., a firm offering financial and strategic services to healthcare and venture capital organizations for the evaluation of M&A and strategic alliances.

Prior to that, he founded in 1987 Clinidata, a software and communication company developed in association with Royal Bank Capital Corporation, which specialized in healthcare applications. Clinidata developed effective and sophisticated technologies supported by multinational corporations such as Merck, Pfizer, J&J, Schering Plough and Smith Kline Beecham, combined with strategic alliances with managed care organizations and professional associations. Clinidata was acquired in 1994 by the pharmaceutical company Hoechst Marion Roussel. In 1980, he created and managed L'Actualité Médicale, a leading Canadian medical publishing company which was later acquired by MacLean Hunter.

Mr. Porte has a degree in Business Administration and Finance from l'École Supérieure de Commerce de Lyon (France) and a D.E.A. in Information Sciences from the University of Sorbonne (France). Mr. Porte is a member of the Board of Directors of Labopharm Inc. He is also the Chairman of the board of Ambrilia Biopharma and of i3 vision.